# A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

> **NCT04969939** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 120 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
- **DRUG:** Semaglutide 2.4 mg and placebo 2.0 mg
- **DRUG:** Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- **DRUG:** Semaglutide 2.4 mg and placebo 1.0 mg

## Key facts

- **NCT ID:** NCT04969939
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2022-12-06
- **Final completion:** 2023-01-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969939, "A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04969939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*